129 related articles for article (PubMed ID: 3115787)
1. Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract.
Jansen RL; van der Burg ME; Verweij J; Stoter G
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1131-3. PubMed ID: 3115787
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors.
Peters WA; Rivkin SE; Smith MR; Tesh DE
Gynecol Oncol; 1989 Sep; 34(3):323-7. PubMed ID: 2767523
[TBL] [Abstract][Full Text] [Related]
3. Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy.
Grosh WW; Jones HW; Burnett LS; Greco FA
Gynecol Oncol; 1986 Nov; 25(3):334-9. PubMed ID: 3023205
[TBL] [Abstract][Full Text] [Related]
4. Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary.
Baker TR; Piver MS; Caglar H; Piedmonte M
Am J Clin Oncol; 1991 Jun; 14(3):246-50. PubMed ID: 2031513
[TBL] [Abstract][Full Text] [Related]
5. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
6. Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer.
Bruckner HW; Cohen CJ; Bhardwaj S; Feuer E; Chesser MR; Holland JF
Eur J Cancer Clin Oncol; 1989 Sep; 25(9):1273-9. PubMed ID: 2509207
[TBL] [Abstract][Full Text] [Related]
7. Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
Richman CM; Podczaski E; Weiser PA; Herbst AL
Oncology; 1986; 43(1):12-7. PubMed ID: 3079898
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
Sessa C; Colombo N; Bolis G; Marsoni S; Mangioni C
Cancer Treat Rev; 1991 Mar; 18 Suppl A():37-46. PubMed ID: 1904308
[No Abstract] [Full Text] [Related]
9. Doxorubicin and cisplatin in the treatment of advanced mixed mesodermal uterine sarcoma.
Seltzer V; Kaplan B; Vogl S; Spitzer M
Cancer Treat Rep; 1984 Nov; 68(11):1389-90. PubMed ID: 6541972
[No Abstract] [Full Text] [Related]
10. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus.
Gershenson DM; Kavanagh JJ; Copeland LJ; Edwards CL; Stringer CA; Wharton JT
J Clin Oncol; 1987 Apr; 5(4):618-21. PubMed ID: 3559652
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer.
Bruckner HW; Cohen CJ; Goldberg JD; Kabakow B; Wallach RC; Deppe G; Reisman AZ; Gusberg SB; Holland JF
Am J Obstet Gynecol; 1983 Mar; 145(6):653-8. PubMed ID: 6402934
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide, vincristine, adriamycin, and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital tract.
Piver MS; DeEulis TG; Lele SB; Barlow JJ
Gynecol Oncol; 1982 Dec; 14(3):319-23. PubMed ID: 6897542
[No Abstract] [Full Text] [Related]
13. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
Levin L; Hryniuk W
Semin Oncol; 1987 Dec; 14(4 Suppl 4):12-9. PubMed ID: 3120317
[TBL] [Abstract][Full Text] [Related]
14. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial.
Hempling RE; Piver MS; Baker TR
Am J Clin Oncol; 1995 Aug; 18(4):282-6. PubMed ID: 7625366
[TBL] [Abstract][Full Text] [Related]
15. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
Levin L; Simon R; Hryniuk W
J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
[TBL] [Abstract][Full Text] [Related]
16. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D
Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP).
Bruckner HW; Cohen CJ; Deppe G; Kabakow B; Wallach R; Ratner L; Holland JF
Gynecol Oncol; 1981 Oct; 12(2 Pt 1):150-3. PubMed ID: 6795095
[No Abstract] [Full Text] [Related]
19. HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
Coleman M; Pasmantier MW; Silver RT
Cancer; 1985 May; 55(10):2342-7. PubMed ID: 3921228
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Heintz AP; van Lent M; Trimbos JB; Bouma J; Vermorken JB
J Clin Oncol; 1987 Aug; 5(8):1157-68. PubMed ID: 3114434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
